A randomized placebo-controlled trial tested three concentrations of smoked cannabis (high THC, high CBD, THC+CBD) against placebo in military veterans with PTSD. Over three weeks, all groups including placebo showed significant improvements in PTSD symptom severity, but none of the active cannabis concentrations outperformed placebo statistically. The treatments were generally well tolerated. This preliminary trial did not find evidence that smoked cannabis is more effective than placebo for PTSD symptoms in the short term, highlighting the need for further well-powered studies.
MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD) not only reduces symptoms but also promotes posttraumatic growth (PTG)—positive changes in self-perception, relationships, and life philosophy. Pooled data from three phase 2 clinical trials with 60 participants showed that those receiving active MDMA (75–125 mg) had significantly more PTG and larger reductions in PTSD symptom severity at the primary endpoint compared to the control group (0–40 mg MDMA). At 12-month follow-up, PTG remained higher, symptom severity lower, and two-thirds of participants no longer met PTSD criteria. These large-magnitude effects suggest PTG may be a new mechanism of action for this treatment.